Company intelligence / Profile preview

Forsea

Ownership: Private
Development stage: Preclinical

Overview

Forsea has developed a proprietary organoid technology enabling efficient, scalable production of cell-cultured fish and seafood. Their lead product is freshwater eel ("unagi"), addressing both sustainability and supply challenges. The platform recently achieved record-breaking cell density (>300 million cells/ml), positioning the company at the forefront of cost-effective cultured seafood production. No clinical results are relevant as this is a foodtech application, but their R&D milestones have been significant in terms of scalability and product quality.

Modalities: Organoid-based cell cultivation
Industry: Non-Drug Biotech

Beyond the preview

Go deeper on Forsea.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Forsea.

Explore the full profile